Literature DB >> 28619258

Rho kinase-dependent desensitization of GPR39; a unique mechanism of GPCR downregulation.

Yuji Shimizu1, Ryokichi Koyama2, Tomohiro Kawamoto2.   

Abstract

GPR39, a G-protein-coupled receptor activated by zinc, reportedly activates multiple intracellular signaling pathways via Gs, Gq, G12/13, and β-arrestin, but little is known about downregulation of the receptor upon its activation. To our knowledge, this is the first report on the mechanism of feedback regulation of GPR39 function determined in GPR39-expressing HEK293 cells (HEK293-GPR39) as a model cell system. In HEK293-GPR39 cells, GPR39-C3, which is a positive allosteric modulator, activated cAMP production (downstream of Gs), IP1 accumulation (downstream of Gq), SRF-RE-dependent transcription (downstream of G12/13), and β-arrestin recruitment. GPR39-C3 induced dose- and time-dependent loss of response in cAMP production by second challenge of the compound. This functional desensitization was blocked by the Rho kinase (ROCK) inhibitor, Y-27632, but not by Gq or Gs-pathway inhibitors or inhibition of β-arrestin recruitment. In the receptor localization assay, GPR39-C3 induced internalization of GFP-tagged GPR39. This internalization was also inhibited by Y-27632, which suggested that ROCK activation is critical for internalization and desensitization of GPR39. A novel biased GPR39 positive allosteric modulator, 5-[2-[(2,4-dichlorophenyl)methoxy]phenyl]-2,2-dimethyl-1,3,5,6-tetrahydrobenzo[a]phenanthridin-4-one (GSB-118), which activated cAMP responses and β-arrestin recruitment but showed no effect on SRF-RE-dependent transcription, did not induce desensitization. These results revealed a unique mechanism of desensitization of GPR39.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biased ligand; Desensitization; G-protein-coupled receptor 39; GPR39-C3 (PubChem CID: 091826086); GSB-118 (PubChem CID: 003112012); Positive allosteric modulator; Rho kinase

Mesh:

Substances:

Year:  2017        PMID: 28619258     DOI: 10.1016/j.bcp.2017.06.115

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  7 in total

1.  Rare-variant pathogenicity triage and inclusion of synonymous variants improves analysis of disease associations of orphan G protein-coupled receptors.

Authors:  Ridge Dershem; Raghu P R Metpally; Kirk Jeffreys; Sarathbabu Krishnamurthy; Diane T Smelser; Michal Hershfinkel; David J Carey; Janet D Robishaw; Gerda E Breitwieser
Journal:  J Biol Chem       Date:  2019-10-18       Impact factor: 5.157

Review 2.  Zinc-mediated Neurotransmission in Alzheimer's Disease: A Potential Role of the GPR39 in Dementia.

Authors:  Michal Rychlik; Katarzyna Mlyniec
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363

Review 3.  The Zinc-Sensing Receptor GPR39 in Physiology and as a Pharmacological Target.

Authors:  Anna Laitakari; Lingzhi Liu; Thomas M Frimurer; Birgitte Holst
Journal:  Int J Mol Sci       Date:  2021-04-08       Impact factor: 5.923

Review 4.  The Zinc Sensing Receptor, ZnR/GPR39, in Health and Disease.

Authors:  Michal Hershfinkel
Journal:  Int J Mol Sci       Date:  2018-02-01       Impact factor: 5.923

5.  Orchestration of Intracellular Circuits by G Protein-Coupled Receptor 39 for Hepatitis B Virus Proliferation.

Authors:  Kaku Goto; Hironori Nishitsuji; Masaya Sugiyama; Nao Nishida; Masashi Mizokami; Kunitada Shimotohno
Journal:  Int J Mol Sci       Date:  2020-08-07       Impact factor: 5.923

6.  Arrestin-independent constitutive endocytosis of GPR125/ADGRA3.

Authors:  Katja Spiess; Sofie O Bagger; Lola J Torz; Kristian H R Jensen; Anna L Walser; Jone M Kvam; Ann-Sofie K Møgelmose; Viktorija Daugvilaite; Riia K Junnila; Gertrud M Hjortø; Mette M Rosenkilde
Journal:  Ann N Y Acad Sci       Date:  2019-10-29       Impact factor: 5.691

Review 7.  Role of GPR39 in Neurovascular Homeostasis and Disease.

Authors:  Yifan Xu; Anthony P Barnes; Nabil J Alkayed
Journal:  Int J Mol Sci       Date:  2021-07-30       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.